Monthly Archives: May 2013

Targeted Medical Pharma’s President and COO David Silver Comments on Study Showing µ-Opiod Receptors Impaired in Fibromyalgia Patients

Los Angeles, CA, May 31, 2013 — David Silver, M.D., President and Chief Operating Officer at Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, issued the following statement regarding a University of Michigan study highlighted in Pain Medicine News demonstrating the connection between μ-opioid receptor binding and the brain’s response to fibromyalgia pain: “The University of Michigan study confirms widespread consensus within the medical community that fibromyalgia patients respond poorly to narcotics. Additionally, there is no medical evidence Continue reading →

Targeted Medical Pharma to Present at Marcum Microcap Conference

LOS ANGELES, May 22, 2013 — Targeted Medical Pharma, Inc. (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced that its Chief Executive and Chief Science Officer, Dr. William Shell, will be presenting at the Marcum MicroCap Conference.   The conference will be held on Thursday, May 30, 2013 at the Grand Hyatt Hotel, located at 109 East  42nd Street in New York City.  Dr. Shell’s presentation will take place at 4:30 p.m. EST in the Estate Continue reading →

Targeted Medical Pharma Reports 2013 First Quarter Results

— Company Reports Record Revenue through Continued Execution of Growth Plan — Los Angeles, May 15, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced financial results for its first quarter ended March 31, 2013. The Company posted record quarterly revenue of $2.811 million for the first quarter ended March 31, 2013, compared to revenue of $1.375 million for the first quarter ended March 31, Continue reading →